The Use of Statins for Myocardial Death Prevention

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection fraction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction

NCT00611169

Acute Myocardial Infarction

COMPLETED PHASE4

Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients

NCT00945308

Acute Myocardial Infarction

UNKNOWN PHASE2

Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)

NCT00251823

Myocardial Infarction

COMPLETED PHASE3

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

NCT04731155

Early PCSK9 Inhibitor on Ventricular Remodling

RECRUITING PHASE4

BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

NCT00111566

Coronary Artery Disease Myocardial Infarction

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atorvastatin 80 mg

Group Type EXPERIMENTAL

Atorvastatin

Intervention Type DRUG

Oral Atorvastatin

Atorvastatin 10 mg

Group Type EXPERIMENTAL

Atorvastatin

Intervention Type DRUG

Oral Atorvastatin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin

Oral Atorvastatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study.

Exclusion Criteria

1. The impossibility to give the required informed consent.
2. Known allergy to Atorvastatin.
3. Base line serum creatinine of 1.4 mg/dL.
4. Killip Classification 3 and 4.
5. Persisting vomiting.
6. History of previous liver disease.
7. History of previous muscle disease or rabdomyolisis.
8. Treated already with high dose atorvastatin
9. Non Compliance.

Minimum Eligible Age

30 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No